Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from GDRX

3 Pharma Powerhouses to Boost Your Year-End Investments

Backed by an ever-growing need for chronic disease treatments, rapid investments in research and development, and widespread integration of technology, the pharmaceutical sector is anticipated to flourish. Thus, as we approach the end of 2023, three solid pharma stocks, GoodRx Holdings (GDRX), CytomX Therapeutics (CTMX), and Neurocrine Biosciences (NBIX), could…

Under $15 Bargains: 3 Pharma Stocks to Watch

Under $15 Bargains: 3 Pharma Stocks to Watch

The pharmaceutical industry is anticipated to remain resilient, owing to increasing healthcare expenditure. Given this backdrop, it could be wise to watch quality pharma stocks Organon & Co. (OGN), GoodRx Holdings (GDRX), and Viatris (VTRS) trading under $15 now. Read on….

3 Resilient Pharma Stocks to Buy This Week

3 Resilient Pharma Stocks to Buy This Week

Amid rising global medical needs and advancement in technology, the pharma industry is expected to witness robust growth in the coming years. Given this backdrop, resilient pharma stocks such as Spero Therapeutics (SPRO), GoodRx Holdings (GDRX) and Kamada (KMDA) might be solid buys now. Read on.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

3 Pharma Stocks Ready to Shine This Week

The pharmaceutical industry is expected to thrive, driven by the increasing need for chronic disease management and the requirements of an aging demographic. Given the industry’s solid prospects, quality pharma stocks Organon (OGN), GoodRx Holdings (GDRX), and Collegium Pharmaceutical (COLL) could be solid buys this week. Read on….

3 Pharma Stocks to Buy Now for a Dose of Profit

The pharmaceutical sector is expanding due to advanced technologies such as AI and new drug discoveries. Hence, quality pharma stocks GoodRx Holdings (GDRX), Merck & Co. (MRK), and Sanofi (SNY) might be profitable investments right now. Read on.

GoodRx Shares Tumble As FY22 Guidance Hit By Grocery Chain Prescription Dispute

GoodRx Holdings Inc (NASDAQ: GDRX) shares fell after it expects FY22 revenue to take a hit due to recent actions by one grocery store chain that represents a sizable chunk of its grocery prescription business.

3 Healthtech Stocks Wall Street Predicts Will Rally More Than 40% or More: GoodRx, 23andMe, and Exact Sciences

The COVID-19 pandemic has accelerated digital adoption in healthcare. And because this trend is attracting massive investments into digital health care, Wall Street analysts expect popular health tech stocks Exact Sciences Corp (EXAS), GoodRx Holdings (GDRX), 23andMe (ME) to rally in price soon. Read on.

inkl

Read news from The Economist, FT, and more,
with one subscription

TherapeuticsMD Shares Soars After VitaCare Divestiture In $150M Deal

TherapeuticsMD Shares Soars After VitaCare Divestiture In $150M Deal

TherapeuticsMD Inc (NASDAQ:TXMD) has agreed to divest its VitaCare Prescription Services business to GoodRx Holdings Inc (NASDAQ:GDRX) for $150 million. VitaCare is a consumer-focused digital healthcare platform. TherapeuticsMD will also receive an additional $7 million in cash consideration contingent upon vitaCare's financial performance through 2023. TXMD will also enter into a long-term services agreement to…

GoodRx Plunges As Q4 Fall Short Of Expectations, Analysts Cut Price Target

GoodRx Plunges As Q4 Fall Short Of Expectations, Analysts Cut Price Target

Consumer-focused digital healthcare, GoodRx Holdings Inc (NASDAQ: GDRX) shares are plunging after the company's

Why GoodRX Shares Are Plummeting Today

Why GoodRX Shares Are Plummeting Today

GoodRx Holdings Inc (NASDAQ: GDRX) is plunging Tuesday after the company reported worse-than-expected fourth-quarter financial results and issued guidance below estimates.

Where GoodRx Holdings Stands With Analysts

Where GoodRx Holdings Stands With Analysts

Over the past 3 months, 7 analysts have published their opinion on GoodRx Holdings (NASDAQ:GDRX) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

1

People

Sristi Suman JayaswalThe

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Medical Pharmaceuticals

GoodRx Holdings

inkl

Read news from The Economist, FT, and more,
with one subscription

Places

231,431 stories

The United States

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play